Abstract
The efficiency of optimal experimental designs when the primary endpoint is immediate is well documented. Often, however, in the practice of clinical trials there will be a delay in the response of clinical interest. Since few patients will have experienced the endpoint in the early stages of a trial, there may be little information that can be used in making a decision to modify the trial’s course. But almost always, the clinical efficacy endpoint will be measured at early time points and these measurements might be correlated with, and predictive for, the primary long-term endpoint. The focus of the definitive analysis is still the primary clinical endpoint and not these short-term endpoints. The latter may be used just as an estimate of potential treatment effect and can enhance the interim decision of dropping a treatment arm or changing the treatment allocation. The research questions are: what is the optimal number of measurements per patient and what are the optimal time intervals between these measurements? A major benefit of modeling relationships between early and late endpoints is that it makes for stronger interim assessments of long-term endpoints and therefore improves the efficiency of adaptive designs.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Atkinson, A.C., Donev, A.N., Tobias, R.D.: Optimum Experimental Designs with SAS. Oxford University Press, Oxford (2007)
Dragalin, V., Fedorov, V.V.: Adaptive designs for dose-finding based on efficacy-toxicity response. J. Stat. Plan. Inference 136, 1800–1823 (2006)
Dragalin, V., Hsuan, F., Padmanabhan, S.K.: Adaptive designs for dose-finding studies based on sigmoid Emax model. J. Biopharm. Stat. 17, 1051–1070 (2007)
Dragalin, V., Bornkamp, B., Bretz, F., Miller, F., Padmanabhan, S.K., Perevozskaya, I., Pinheiro, J., Smith, J.R.: A simulation study to compare new adaptive dose-ranging designs. Stat. Biopharm. Res. 2, 487–512 (2010)
Fedorov, V., Hackl, P.: Model-Oriented Design of Experiments. Springer, Berlin (1997)
Fu, H., Manner, D.: Bayesian adaptive dose-finding studies with delayed responses. J. Biopharm. Stat. 20, 1055–1070 (2010)
Gagnon, R., Leonov, S.: Optimal population designs for PK models with serial sampling. J. Biopharm. Stat. 15, 143–163 (2005)
Leonov, S., Miller, S.: An adaptive optimal design for the Emax model and its application in clinical trials. J. Biopharm. Stat. 19, 360–385 (2009)
Li, W., Fu, H.: Bayesian optimal adaptive designs for delayed-response dose-finding studies. J. Biopharm. Stat. 21, 888–901 (2011)
Muirhead, R.: Aspects of Multivariate Statistical Theory. Wiley, New York (1982)
Padmanabhan, S.K., Dragalin, V.: Adaptive Dc-optimal designs for dose finding based on a continuous efficacy endpoint. Biom. J. 52, 836–852 (2009)
Pronzato, L.: One-step ahead adaptive D-optimal design on a finite design space is asymptotically optimal. Metrika 71, 219–238 (2010)
Shargel, L., Wu-Pong, S., Yu, A.B.C.: Applied Biopharmaceutics & Pharmacokinetics, 5th edn. McGraw-Hill Medical, New York (2004)
Thomas, N.: Hypothesis testing and Bayesian estimation using a sigmoid Emax model applied to sparse dose-response designs. J. Biopharm. Stat. 16, 657–677 (2006)
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer International Publishing Switzerland
About this paper
Cite this paper
Dragalin, V. (2013). Optimal Design of Experiments for Delayed Responses in Clinical Trials. In: Ucinski, D., Atkinson, A., Patan, M. (eds) mODa 10 – Advances in Model-Oriented Design and Analysis. Contributions to Statistics. Springer, Heidelberg. https://doi.org/10.1007/978-3-319-00218-7_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-00218-7_7
Publisher Name: Springer, Heidelberg
Print ISBN: 978-3-319-00217-0
Online ISBN: 978-3-319-00218-7
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)